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Abstract     
Background This article examines community responses to the marketing of prescription medicines. 
Historically, debates about such marketing have focused on alleged unscrupulousness of 
pharmaceutical companies and on the quality of information provided. 
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Methods Six focus groups were conducted in Sydney, Australia, three with older and three with 
younger community members. Analysis examined interactions between group members, the 
positions participants took up, conflicting arguments, and explanations for variation. 
Results Participants argued specifically rather than generally about consumer marketing of 
medicines. Neither the moral purpose of corporations nor the quality of information in 
advertisements was particularly important. Instead, pharmaceutical marketing was assessed in 
relation to vulnerabilities that existed in individual consumers, in doctors, in the contexts of illness 
and as a result of medications being potentially dangerous. 
Conclusions The critical ethical issue in prescription medicine marketing may be the existence of 
vulnerabilities and the responsibilities they may generate. We outline three possible policy 
responses suggested by these participants.  
 
Key words: DTCA, direct-to-consumer advertising, marketing, vulnerability, doctor-patient 
relationship, drug industry 
 
Introduction  
This article reports on an Australian qualitative study examining lay people’s responses to the 
practice of marketing prescription medicines to consumers (henceforth referred to as consumer 
marketing of medicines). In most markets, medicines are promoted via media including television, 
radio, magazines, the Internet, billboards and other outdoor advertising, and consumer group 
sponsorship. However jurisdictions vary according to whether consumer marketing of prescription 
medicines may legally include brand names or detailed claims about the therapeutic benefits of a 
drug.  The inclusion of brand names and health claims is legal only in the United States of America 
(USA) and in New Zealand (NZ). In other jurisdictions, including the United Kingdom (UK), Canada, 
the European Community and Australia, where this study was conducted, the inclusion of brand 
names in consumer marketing of prescription medicines is illegal. However even in these markets, 
pharmaceutical companies commonly engage in unbranded marketing which encourages consumers 
to ‘ask their doctor’ about a specific health condition treated by the company’s drug.  These 
practices often test the limits of regulatory regimes, are largely self-regulated by industry, and have 
been widely criticized, leading to debates about impacts on consumers, and about the proper 
regulation of pharmaceutical industry communications (Australian Consumers Association; 
Australian Medical Association).  In Australia, for example, a review recommended that Australia 
continue to prohibit branded advertisements for prescription medicines to consumers (Galbally 
2001), and concluded that industry self-regulation or co-regulation using a code of practice would be 
unlikely to achieve the necessary controls. Nonetheless, arguments continue to be made 
internationally that such prohibitions are an inappropriate restriction on liberty in an area where 
there is no demonstrable harm.  
In both the USA and NZ, where branded consumer marketing of medicines is legal, spending 
on such marketing has increased rapidly during the last decade: in the USA, it rose from an 
estimated $375 million in 1995 to $4.2 billion in 2005 (U.S. General Accounting Office 2006). This 
increase has sparked vigorous debate, but, as is common on issues of corporate ethics and social 
responsibility, the discourse has been polarized with opposed groups staking claims and counter 
claims. Advocates of consumer marketing of medicines claim that it informs and empowers patients, 
leads to better exchange of information in patient-doctor encounters and to the detection of 
untreated disease, fosters compliance, strengthens the doctor-patient relationship, increases patient 
awareness of health issues and ultimately increases health overall (Bonaccorso and Sturchio 2002; 
Holmer 2002). Opponents counter that it reinforces the link between disease and drug treatment, 
exaggerates the need for and benefits of treatment while de-emphasizing the risks, and exploits the 
 3 
fears and concerns of consumers by misleading and misinforming, thereby motivating clinical action. 
It is also argued that consumer marketing of medicines creates tension between patients, doctors 
and insurers, diverts doctors’ attention away from more pressing health concerns, and inevitably 
increases inappropriate demand for new and expensive drugs, health care costs and net ill-health 
(Mintzes 2002; Moynihan et al. 2002; Vogel  et al. 2003; Woloshin  et al. 2001).  
If sound policy decisions are to be made about consumer marketing of medicines the debate 
needs to move beyond formulaic rhetoric. One way to make this move is to engage with consumers, 
the targets of this marketing. Research about consumer marketing of medicines has focused on 
branded advertising of drugs, has been largely quantitative and survey-based, and has emanated 
primarily from the USA, and to a lesser extent NZ, Canada, and Australia (Alliance for Access to 
Medical Information (AAMI) 2002; Hoek et al. 2004; Miller and Waller 2004). These studies have 
focused on consumer awareness of marketing, consumer preferences regarding the content of 
marketing, and consumer attitudes towards marketing. The results suggest several important 
patterns. As the prevalence of branded consumer marketing of medicines has increased, consumer 
awareness of this marketing has also increased (Prevention magazine 2008; Prevention Magazine 
2005; 2006; Prevention magazine 2007), particularly among consumers taking medications or 
positively disposed towards marketing (Bell et al. 1999a). Consumers have consistently expressed a 
desire for information on indications and drug side effects (Foley and Gross 2000; Tucker and Smith 
1987; Woloshin et al. 2004; Young et al. 2005). In opinion and attitude research, consumers have 
generally been found to have ‘neutral’ or ‘positive’ attitudes to consumer marketing of medicines as 
a source of information (Alliance for Access to Medical Information (AAMI) 2002; Bell et al. 1999a; 
Beltramini 2006; Gonul et al. 2000; Herzenstein et al. 2004; Hoek et al. 2004; Huh et al. 2004a; Huh 
et al. 2004b; Miller and Waller 2004; Murray et al. 2004; National Consumers League 2003; Perri and 
Nelson Jr. 1987; Robinson et al. 2004; Vatjanapukka 2004). However exposure to consumer 
marketing of medicines does not appear to improve the accuracy of consumers’ knowledge about 
drugs (Brodie 2001; Hoek 2007; Kaphingst et al. 2005), and consumers generally express skepticism 
about the quality and credibility of information provided by such marketing and conflicting, diverse 
or inconsistent attitudes on the benefits and risks posed by it (Alperstein and Peyrot 1993; Foley and 
Gross 2000; Herzenstein et al. 2004; Marinac et al. 2004; Miller and Waller 2004; Robinson et al. 
2004; Young et al. 2005b).   
The inconsistencies in the findings of existing survey-based studies are difficult to explain. 
This is a common epistemic problem for quantitative inquiry. Quantitative techniques permit 
consistent measurement of fixed variables in large random samples of the population, producing 
population ‘average’ statistics about, for example, ‘agreement’ or ‘opinions’, which can then be 
readily compared. However the converse of this strength is a weakness: quantitative studies need to 
reduce complex issues to a small set of predetermined variables and draw conclusions about an 
‘average’ person. Qualitative inquiry, conversely, cannot produce representative ‘average’ 
measurements. However it can approach problems naturalistically, investigate the experience of 
specific, contextualized individuals, and discover new variables and relationships of importance 
during investigation by allowing participants to respond on their own terms and provide 
explanations. Thus qualitative techniques, whilst sacrificing statistical representativeness, can 
provide deeper and more original understanding of a complex issue.  
The complexities implicit in marketing prescription medicines to consumers are clearly highlighted in 
both the quantitative empirical research, and the ongoing ethical and policy debates. It is surprising, 
then, that very few qualitative studies have been conducted regarding this form of marketing.  
Young and his colleagues investigated perceived information needs and the degree to which 
consumer marketing of medicines met those needs in focus groups with people who had chronic 
illnesses (Young et al. 2005b). However the knowledge generated did not extend beyond what had 
already been derived from quantitative studies. With this background in mind, we undertook to 
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better use qualitative inquiry to investigate lay people’s responses to the practice of marketing 
prescription medicines directly to consumers. Specifically, we aimed to evaluate:  
1. how lay people construct this practice in group interactions;  
2. the context in which lay people make sense of this practice; and 
3. the arguments lay people use regarding this practice. 
To achieve these aims, we conducted focus groups in which we showed respondents 
hypothetical examples of consumer marketing of medicines. We created these as stimuli for group 
discussion. These illustrations of marketing activities were for fictional brands but were based on 
real marketing practices from Australia, USA and NZ.  Some of the conversations we report on thus 
concern illegal marketing practices that do not exist in Australia and would not have been 
experienced by participants in their ‘real life’. This was deliberate, because we thought it 
conceivable that interested parties may attempt to legalize these practices in Australia in future, and 
thus we were interested in participants’ reactions to them. The exemplars used were concrete and 
well-illustrated, and were explained clearly to the participants.  
Based on our findings we will argue that these participants rarely drew on traditional anti-
corporate rhetoric in their conversations and that the poor quality of information in consumer 
marketing of medicines was not a basis for automatic rejection of such marketing. Instead 
arguments relied on invoking doctors’ and patients’ vulnerabilities in different situations, and the 
responsibilities that these vulnerabilities may or may not entail for policy makers and practitioners.   
 
Methodology and methods  
This study employed focus group methods. Six groups were conducted in Sydney, Australia, three 
with people under the age of 50 and three with people 50 and over. This division was intended to 
create a generationally more homogeneous and thus interpersonally safer environment (Barbour 
and Kitzinger 1999; Morgan and Scannell 1998). As most people use prescription medications at 
some time in their life and this was not considered to be a particularly sensitive issue, we did not 
divide groups according to medication use, although we expected that the older participants were 
more likely to be regular prescription medication users. Participants were recruited via 
advertisements in  local free press distributed directly to households and offices in Sydney. We 
targeted a 15km radius around the focus group location, which included the busy Central Business 
District and residential areas from high to low socioeconomic status (SES). The advertisement read: 
Would you like to participate in a research project? Researchers from The University of Sydney want 
to hear your ideas about drug companies advertising their drugs to people in the community. A 
group discussion will be held in June at Sydney University, Camperdown, for approximately 2 hours. 
You will be reimbursed for your time. In all 40 participants attended; each group contained between 
5 and 8 participants. Groups were of mixed gender and a wide range of SES, each group had 
approximately equal numbers of men and women. Participants were offered $AUD50 compensation 
for their attendance.  
Each group lasted 90 minutes and followed the same basic format, although participants had 
considerable freedom to direct the conversation. After a neutral ‘warm-up’ question, and a general 
discussion about advertising, including advertising medicines, the moderator introduced two 
separate activities. In the first written task, participants were asked to rate the following statements 
on a 5-point Likert scale from "Very important" to "Not at all important": Ads make people think 
they are sick, Drug companies have a right to communicate, Ads provide misleading biased 
information, Ads promote expensive brand-name drugs, An ad might tell you about a drug you need, 
Ads create demands that use up doctors’ time, Ads promote drugs that aren’t proven safe, Doctors 
prescribe whatever patients ask for, Drug ads raise general health awareness. The rationales for 
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their ratings were then freely discussed and compared. Written ratings were not recorded, as this 
was not the purpose of the exercise. It was designed to expose participants to common rhetoric, 
allow time for them to consider, and encourage expression of contrasting evaluations of the various 
arguments, thus moving beyond simple reproduction of well-rehearsed positions.  
In a second exercise, participants were given a set of cards illustrating different 
pharmaceutical marketing activities. They were asked to imagine that they were law-makers, and to 
sort the activities into three piles: ban, approve and send to a committee (the latter meaning 
‘undecided’). This was done individually. When sorting was complete, an open discussion of the 
process of decision-making was facilitated. Again the purpose was not to enumerate responses, but 
to provide concrete examples of marketing for discussion, allow time for private reflection, and 
encourage clarification of the means by which individuals had evaluated marketing practices. In the 
final 10 minutes, the moderator told the participants about a meeting with decision-makers planned 
for the end of the project, and asked what messages they would most like us to take to those 
decision makers.  
As analysts, we understood that these focus groups were, above all, interactions between 
groups of strangers. This is reflected in our presentation of data below which, consistent with 
contemporary standards in focus group reporting, presents interactions rather than 
decontextualized statements from individuals. In these data excerpts, ‘I’ represents the interviewer, 
‘F’ represents a female participant and ‘M’ a male participant. We did not approach analysis 
assuming that we could access the true opinions, beliefs or attitudes of participants – in fact we did 
not presume that such things existed in a static form. Rather, we were interested in the positions 
that people took up in this forum. This reflects both the broadly constructivist theoretical 
perspective that we bring to qualitative inquiry (Charon 2007) and a rejection of the naïve 
methodological reasoning which treats focus group data like any other data (Barbour and Kitzinger 
1999).  
Each group was transcribed in detail by a professional transcriber. Initial detailed coding (at 
a line-by-line level), consistent with our interactionist perspective, focused on process and action, 
encoding what participants were doing with their talk and how they were constructing and 
modifying meaning together. This coding, and comparison between and within groups, was used to 
develop models of the sense-making processes participants enacted, with particular attention to the 
positions that they took up, conflicting arguments, and explanations for variation. We did not use 
computer-aided data analysis software: we annotated directly onto transcripts in Microsoft Word 
and used mind-mapping software (Inspiration 2007) to relate and develop concepts. Analysis was 
conducted cooperatively by two of the authors (GS and SMC) and discussed with the research team 
as it evolved. In the interests of confidentiality, all names in the focus group transcripts were 
changed to pseudonyms. 
The study protocol was approved by the University of Sydney Human Research Ethics 
Committee.  
 
Findings  
Participants argued specifically rather than generally about consumer marketing of medicines. 
To begin, it should be noted that people argued about the acceptability of consumer marketing of 
medicines in the context of the specific drug, consumer, illness, and prescriber in question, and 
different contexts changed the positions people took up. Rather than outright rejection or 
acceptance of marketing, participants often argued that ‘it depends’. Three key issues within and 
across participants’ accounts explained rejection or acceptance of marketing practices: these were 
the dimensions along which it ‘depended’. Participants distinguished between active consumers and 
vulnerable consumers. They argued that whilst they wanted access to good information about 
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medicines, marketing campaigns could not provide such information: they could only alert to the 
existence of a drug. The appropriateness of such an alert depended on whether one was an active or 
a vulnerable consumer. Finally, participants talked about ‘good’ and ‘bad’ doctors, and the 
significance of their relationships with active or vulnerable consumers.  We will discuss each of these 
issues in turn.  
 
The active consumer versus the vulnerable consumer 
F … I think you know, if you've got the Internet, I'm on 14 prescription drugs. Every time I'm 
given a new one, okay I get it, but first I go home, look it up on the Internet, look at all the 
information, probably spend an hour, two hours on it before I take it. Now once I've done that, ads 
quite frankly don’t count. 
I Interesting. 
F But I would say a lot of elderly people. 
F That's right. 
F That's, that’s true, but every chemist now, when you get your prescription, you can ask for a 
printout, and I think people really must read that, because your doctor often doesn’t really think 
through that you're on the 11 … other 11 drugs. 
[…] 
M Can I just say something… I was going to say like that's a … all this is sort of on the 
presumption that people sort of generally worry about their drugs, I don’t think they do actually. 
F No, I agree. I think … 
M They just throw them down and that's it. 
F I disagree with that. 
F The elderly people now that I'm looking after and I've found that quite honestly, the doctor 
said ‘Take this tablet.’ They will take it and they really don’t care what the side effects are, they don’t 
care, except they want to get better or the doctor has said that that's gospel truth. 
I Hm. Interesting. 
F And I think that that's … this is all an age-related thing now, if you're talking about someone 
who's young or even up to middle-aged, I think yes, they will look into it. Anyone elderly. Forget it, 
they just take it blindly. 
F I’d disagree with that (F: Do you?), if you've had a bad experience, you'll never take anything 
else again with that experience. 
       [Group 2, age 50 and over] 
 
As illustrated above, participants’ talk implied two possible subject positions that a consumer could 
take up in relation to pharmaceuticals and health in general. These subject positions were pervasive 
in participants’ reasoning about consumer marketing of medicines, as will be shown in subsequent 
sections.  The first position was the active, independent, critical, responsible consumer, seen 
above in the participant who spends two hours on the Internet researching each new drug she is 
given, or the assertion that people ‘really must read’ the information sheets from pharmacists. Most 
participants adopted this position for themselves. Active consumers valued health information and 
awareness, and adopted a highly critical, even untrusting stance towards health professionals, 
particularly doctors, which necessitated seeking health information from a variety of sources.  
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The contrasting subject position was the vulnerable consumer. Vulnerable consumers 
sometimes sought health information, but consumed it uncritically. In our analysis of participants’ 
talk, we saw vulnerable consumers of three ‘types’. Consumers of the first type, who are discussed 
above, were easily controlled, insufficiently self-protective, weak, or unable to stand up for 
themselves. We will refer to this type as ‘compliant consumers’. This could include older consumers 
made frail by age and/or accustomed to highly paternalistic medicine who would ‘blindly’ do as the 
doctor said, persons intellectually ill-equipped to navigate the health system, or persons who were 
simply inattentive to their health. The second type of vulnerable consumer we will refer to as 
‘suggestible questing consumers’. These consumers were those always looking for a new ‘cure’ and 
could be led by advertising to act against their own best interests (that is, demand medicine they 
didn’t need). We will see talk below about such consumers, who see an advertisement and think 
‘well that’s the answer to my problems and I’m going to find a doctor who can give that to me.’ 
‘Suggestible questing consumers’ were often mocked, a joke that was readily shared. They were 
talked about as irresponsible, irrational, even somewhat pathetic. The third type of vulnerable 
consumer we will refer to as ‘seriously ill consumers’. These very sick (especially fatally ill) 
consumers were driven by the severity of their illness to completely trust their doctors or accept any 
treatment, and thus became vulnerable.  
The ‘vulnerable consumer’ was a dangerous subject position for participants to take up. Only 
a rare, brave participant was prepared to risk ‘outing’ herself or himself as vulnerable, so there was 
little opportunity to observe the ‘vulnerable’ position being enacted. Instead, people frequently 
speculated on ways in which these vulnerable ‘others’ would be more susceptible to marketing.  
 
Appropriate access to health and drug information  
F Well I’m reading up about the new cervical vaccination the Gardisil um, and it has been 
direct advertising to the consumer and I was very dismayed to find out that actually the latest news 
is that it’s cost a lot of bad side effects (F: that’s right) and all that and I thought you know they 
should be advertising it all, in total all the details and everything to the GPs [general 
practitioners/family physicians] before they you know targeting it at the consumer because the 
consumer is not very – is not able to really understand these things from a more, (indistinct) 
maximal value, er, viewpoint.  
I Right so you can’t get an informed decision? 
F Yeah because the GPs are responsible for a lot of things. You know?  
F Yeah that’s a – it’s a good point but you see on the other hand that if you don’t advertise it 
to the consumer they’re not going to go to the doctor and ask, just in general, what can I do to 
improve my health? Most people aren’t going to do that so I mean that one you’re talking about is it 
Gardisil (F: yeah Gardisil) the new one, I think that it’s probably a good one to advertise because if 
your doctor didn’t tell you about that you’d miss that 9 month period where the government’s doing 
it for free for all women under a certain age, or just if you didn’t happen to go to the doctor in that 
period. You kind of miss out on that. I sort of think you need to know something like that (indistinct) 
is so beneficial. 
[…] 
F […] I would only pay attention to anything that was relevant to me and it’s sometimes good 
to see choices. Um, so I actually think it would be a good thing. 
[…] 
F …This Gardasil, they found in the States that this actually caused cancer. There was another 
bit of information that was left out in the, direct, it was been advertised directly to the consumer. So 
I think that’s terrible you know.  
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I So the idea of drug safety is a bigger issue for you? 
F Yes. Yes. 
I Yeah they shouldn’t advertise any drugs that aren’t safe.  
M How much information can you put in 30 seconds?  
F It’s kind of a hard call too because I think advertising drugs, you’ve got to be careful because 
if you’re mixing it with something else you, you’ve got to be really careful you can’t just take what’s 
advertised as gospel. 
I Right 
F Yeah because there’s so many variations of the individual person. 
F Yeah I think to add to that and you have the issue of drug interaction you know. I mean if 
you’re on 10 or more different drugs a day my goodness, you could be a very bad, fatal cocktail like 
the case of I think Heath Ledger you know  
[…] 
F …Certain drugs that you know should be very seldom prescribed, at the time I mean look at 
Prozac, it was considered to be a cure-all for everything and it’s got a horrendous, but if someone’s 
very depressed and they see these happy-looking Prozac ads then they could really convince 
themselves, ‘Well that’s the answer to my problems and I’m going to find a doctor who can give that 
to me.’ 
F Yeah. 
M Maybe the drugs need to be categorized like my reaction would be different to different 
categories. I don’t know what the categories are (I: Right yeah) but you know this drug on TV, fine, 
this one not fine (I: Yes) this one maybe perhaps you know. 
       [Group 7, age 50 and under] 
 
The provision of information was a key issue in participants’ discussions. Consistent with other 
research, participants in this study said they wanted to receive extensive accurate information about 
health, and that ‘people’ should be made more aware of their health. This was sometimes 
constructed as a right and sometimes a means by which one could help others. This desire for 
information was a common backdrop to discussions about marketing of medicines, exemplified 
above in the implicit framing of Gardasil as something ‘I can do to improve my health’, and the 
concern about missing such opportunities if one’s awareness was not raised through marketing.  
Also consistent with existing research, participants were very concerned about drug safety: 
there was an almost universal desire expressed for comprehensive, comparative information about 
drugs and side effects. This is seen above in the ‘dismay’ about the alleged serious side effects of 
Gardasil, about ‘very bad, fatal cocktail(s)’ of drugs, and the statement, commonly made, that ‘they 
shouldn’t advertise any drugs that aren’t safe’. Many participants traced their desire for drug 
information back to an experience of drug side effects, and worried out loud that they were ill-
informed about side effects and contraindications. Implicit in these discussions was a clear 
differentiation made between types of or particular drugs, as reflected above: drugs had different 
profiles of potential harm or benefit, and could be inherently unpredictable.  
These participants were unified by a desire to receive health information and drug safety 
information. However they generally agreed that consumer marketing of medicines was a poor 
source of health information and was never sufficient to inform consumers about side effects.  Drug 
marketing was always spoken of as misleading, biased and coercive. It was not possible to inform in 
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the time and space allotted to advertisements or in the inherently persuasive marketing genre. For 
this reason, advertisements could not inform, they could only alert. This was a general truism, such 
that it would be considered misguided and ridiculous to argue for advertisements as a source of 
information. Advertisements could act only as an alert, to make people aware, indicating that a 
product or service existed. Information – real information – came from sources including 
pharmacists, doctors, one’s own research on the Internet or professional medical publications, and 
stories from friends and family. Branded drug marketing was particularly problematic in these 
conversations: the addition of a brand trivialized medicines, made the communication inevitably 
commercial, and decreased its acceptability. 
Arguments did not hinge on whether marketing informed: it clearly did not. The critical issue 
was whether or not an alert was a useful or acceptable thing. The degree to which an alert was 
acceptable depended on the profile of the drug, the subject position of the consumer, and the 
responsibilities taken towards different types of consumers.  
As noted above, most participants framed themselves as active consumers. However active 
consumers took a variety of positions on the acceptability of alerting, demonstrated in the sample 
interaction above. Active consumers sometimes expressed concern about drug safety, but said this 
concern was not sufficient to prevent marketing. Despite its shortcomings, marketing alerted 
people, stimulating health awareness, personal research and visits to the doctor. Even if a drug had 
significant safety issues, active consumers should be informed and judge for themselves, evaluating 
marketing as they would any other source of information.  
This position was resisted by other participants in several ways. One was to argue that alerts 
were not useful, even for active consumers. Another was to propose conditions for prohibiting 
marketing. The first condition for prohibition was when drugs had not been proven to be safe, or 
when their side effects were not known (this creates difficulties for regulators which we will come to 
in our discussion). In this case, drug safety concerns overrode the desire to be generally informed. 
The second prohibitive condition was when the drug treated extreme or life threatening illness. We 
have already seen the concern expressed for ‘seriously ill consumers’, made vulnerable by the 
situation of their illness. Because of this concern, consumer marketing of medicines for life-
threatening illnesses was generally talked about as flippant, trivializing, and unacceptable. Seriously 
ill consumers needed a trustworthy doctor, not marketing of medicines.  
Finally, some active consumers argued that marketing would always be problematic, 
because of ‘suggestible questing consumers’ and ‘compliant consumers’. These vulnerable people 
would consume marketing campaigns uncritically or irresponsibly, and it was more important to 
protect them than it was to provide an alert to active consumers. 
 
Health professionals and ‘doctor shopping’  
M Um, I think it’s worth that we are going to, it’s really going to conjure up the idea that 
virtually it’s a supermarket now at the doctor’s surgery [consulting rooms] and you can go in and ask 
for what you want and if the doctor doesn’t give it to you then you’re going to find a doctor who 
does.  So they are all going to start having to do it. 
I How do other people feel about that idea about the doctor’s surgery? 
M I agree a lot with what Bill’s saying.  
I So you’re nodding your head Jane. 
F Yeah, I know that I’ve probably got two or three doctors depending on whether I’ve got the 
time to sit around in the waiting room mainly, or not and one time I went to the 24 hour medical 
centre and I said look - it was the honest truth my regular doctor wouldn’t give me this, this or this 
and she just gave me all three scripts. (Hm) I was in and out in less than five minutes.  So I mean if I’d 
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shopped around doctors to find one that would eventually give me something that I wanted, I would 
have been incredibly happy [laughter].  I was pleased that I did get what I needed and I didn’t have 
to wait around until the you know next business hours to hopefully get an appointment to see my 
usually doctor. But I mean she didn’t even flinch.  She just went okay fine. I knew the name and I 
knew the usual dosage and that was it. 
M So you’re very sort of comfortable with whatever drugs you were taking? 
F Yeah. 
M So it’s not as if you were going in for an ailment that you needed to- 
F Yeah and I did give her the name of the other doctor you know I said he’s closed on the 
weekend, obviously I can’t get in and I’ve run out of whatever. 
I How do you feel about that idea that doctors can just give people drugs? 
F Well it was a bit worrying because she didn’t question me at all and she didn’t give me a 
smaller script, say enough tablets to then go and wait for my regular doctor.  She just gave me a full 
two months prescription [laughter]. 
M God love them. 
F Yeah, and I just thought hm do you get paid by the clock or by however many people you 
see or how many scripts you write or - 
I So the question is I suppose does that bother you so much that it would affect your opinion 
as to whether you should advertise prescription drugs? 
F It just worried me that it was it was that easy.  I mean maybe I’ve got an honest face or 
maybe she had something else on her mind or… 
       [Group 5, age 50 and under] 
 
Central to the evaluation of consumer marketing of medicines was concern about whether one 
could trust one’s doctor, and how one navigated the trustworthiness of doctors. The above is just 
one excerpt from the extensive narrative evidence that was presented, by participants of all ages 
and sexes, about the untrustworthiness of some doctors. There were good and bad doctors, and 
good doctors sometimes acted badly due to time pressures or exhaustion. Bad doctors failed to 
prioritize the patient’s interests, spent insufficient time with the patient, and did not provide health 
information, especially about drug side effects. These doctors were vulnerable themselves, to the 
influence of both patients’ requests and the pharmaceutical industry’s communications. They were 
poor gatekeepers with regard to prescribing; thus they facilitated the biomedicalization of society, a 
trend which would be worsened by consumer marketing of medicines. This professional vulnerability 
was just as important as the vulnerability of consumers in evaluating marketing of medicines.  
An important relationship was observed between the trustworthiness of doctors, doctor 
shopping and consumer subject position. Active consumers doctor-shopped to locate a professional 
who could be trusted not to over-prescribe (and participants appeared to have faith in their ability to 
identify trustworthy doctors). In this context, consumer marketing of medicines was more 
acceptable as both the consumer and the doctor would act responsibly towards appropriate 
medicine use. In contrast, the ‘suggestible questing consumer’, influenced by marketing, would 
doctor-shop to find an untrustworthy practitioner who would prescribe freely. So although a 
trustworthy doctor-patient dyad could use consumer marketing of medicines as a resource, because 
of extensive narrative evidence that untrustworthy doctors and ‘suggestible questing consumers’ 
would always exist, marketing remained a potentially pernicious influence.  
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Additional issues 
We note that we did not see important differences between the responses of older and 
younger groups in our analysis. As expected, older people often had a much more extensive 
experience of medication use on which to draw, including experiences of caring for their very elderly 
relatives: perhaps for this reason, they seemed to have greater altruistic concern for the health of 
vulnerable others, and seemed more likely to see prescription drugs as a very serious matter that 
should not be trivialized. Otherwise, the older and younger groups were similar in their responses.  
 
Discussion  
The findings of this study provide an interpretive context for the apparently conflicting or uncertain 
results that have been obtained by previous quantitative research. Some research questions, 
particularly regarding the proportion of consumers who are aware of and can recall prescription 
drug consumer marketing, are best-answered using quantitative techniques. However the form of 
investigation most commonly used in this field – that is, asking consumers to rate on a scale their 
agreement with statements such as ‘advertising of prescription medicines would help consumers 
make better choices’ or ‘advertising prescription medicines is a good idea’ – has effectively 
prevented research participants from saying ‘it depends’, setting out reasons for agreement, 
disagreement, or varying agreement with prescription drug marketing to consumers, and relating 
issues to one another as they did in these focus groups. Qualitative techniques are particularly useful 
for developing complex understandings that go beyond simple agreement or disagreement. 
These participants saw the marketing of prescription medicine to consumers as a poor-
quality and low-credibility information source. This was so obvious that the quality of information 
provided was largely irrelevant to the acceptance or rejection of such marketing. Marketing could 
only ever alert consumers to the existence of a product or service. Attempts to ameliorate the 
negative effects of marketing by improving the ‘balance’ of information presented thus appear to 
miss the point. No matter how hard we try, marketing may never be a good source of information. 
Acceptance of consumer marketing of medicines in this data ‘depended’ on other key dimensions, 
which we argue should take priority in policy debates about consumer marketing of medicines. 
As noted, the traditional pro- and anti-drug marketing debate is, on the whole, a pro- and 
anti-corporate debate, much like the debate on food advertising to children (Senate of the 
Parliament of Australia 2008) and tobacco marketing (Carter 2003). The pharmaceutical industry, 
and experts paid by them, produce commentary in favor of marketing; anti-corporate activists and 
academics produce commentary against it. This contest focuses on critical and structural questions: 
the task, essentially, becomes that of ‘proving’ that industries are fundamentally good or bad, 
socially responsible contributors or ruthless profiteers. Participants in these focus groups instead 
invoked vulnerabilities inherent in patients, inherent in doctors, and arising from situations. Few 
participants positioned themselves as vulnerable, but most participants had at least some concern 
for vulnerable consumers, and about doctors who were vulnerable to influence. This suggests that a 
closer examination of the concept of vulnerability and its conditions and implications can make 
useful and critical contributions to the development of policies about consumer marketing of 
medicines. 
Although most people have an intuitive sense of what ‘vulnerability’ means, many disparate 
definitions are employed in both everyday and technical usage. Recent discussions on this subject 
have focused on two key questions.  The first is a question of generality. Some authors have argued, 
for example, that for ‘vulnerability’ to be a useful concept it is necessary to define it restrictively, so 
as to apply only to subgroups of people (for example, those whose autonomy is compromised 
and/or are unable to protect their own interests from exploitation), thus providing those people 
with a claim to special protection (Hurst 2008; Jecker 2004; Silvers 2004). Opponents to this view 
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argue that vulnerability should be defined as a universal, existential human characteristic, 
ontologically prior to autonomy, the ‘bridging factor between moral strangers’, creating an ethical 
imperative to prevent the wounding that we are all capable of giving and receiving (Finder 2004; 
Jecker 2004; Rendtorff 2002) and thus perhaps providing a justification for the application of a 
general precautionary principle (Grinnell 2004). This debate hinges in part on whether defining 
subgroups as vulnerable is more likely to ensure just treatment of members of that group, or to lead 
to their unjust stigmatization or exclusion (Hurst 2008; Kipnis 2004; Silvers 2004). The second key 
question considers the degree to which vulnerability should be conceptualized as arising from 
situations, contexts or relationships (Finder 2004; Henderson et al. 2004; Hurst 2008; Jecker 2004; 
Levine et al. 2004; O’Neill 1996; Shivas 2004) rather than as merely a characteristic of individuals: 
this question resonates with debates over the degree to which autonomy should be conceptualized 
relationally. 
How do these issues play out in our data? Firstly, vulnerability was not spoken about as an 
existential universal inherent in human beings; the vulnerabilities in these conversations were 
specific aberrations in medicine use which increased the threat of harm to individual patients and 
society at large. We note that we must be cautious about taking these constructions at face value. As 
Shildrick has observed, the vulnerabilities that we see around us may reveal uncomfortable 
vulnerabilities in ourselves, and this discomfort may lead us to forcefully distance ourselves from the 
defective ‘other’ (Shildrick 2000). In fact we are rarely perfect active self-advocates and independent 
information-seekers. A belief in one’s own invincibility to influence may in fact increase one’s 
vulnerability. Participants’ positioning of themselves as non-vulnerable cannot ‘prove’ a restricted 
rather than a universal form of vulnerability. However the talk of these participants does suggest 
types of vulnerability that might be especially relevant to consumer marketing of medicines. We 
have derived five types of vulnerability from this data. Two arose from constructed aberrant ‘traits’ 
of consumers: being suggestible and questing, or being compliant. One arose from a constructed 
aberrant ‘state’ or situation: being seriously ill. The fourth was perhaps the most general form of 
vulnerability, in that it arose from the questionable safety of medicines. Finally, some doctors were 
vulnerable, either consistently or due to circumstance.  
The ‘suggestible questing consumer’ was readily influenced by persuasion, always looking 
for a new cure, and would ‘shop around doctors to find one that would eventually give [them] 
something that [they] wanted’. Participants constructed the ‘suggestible questing consumer’ as 
lacking autonomy – they did not know what was good for them, and thus could not be considered 
self-actualizing (Benson 2000) – but as highly agentic in their search for new medicines. In contrast, 
‘compliant consumers’ were vulnerable both because they took minimal action in relation to their 
health, and because their actions were not self-directed. Their passivity might arise from inattention 
or incompetence: they would ‘take [medicines] and they really don’t care what the side effects are… 
they just take it blindly.’  
‘Suggestible questing consumers’ and ‘compliant consumers’ were vulnerable because of 
individual traits. In contrast, the third form of vulnerability arose from a (possibly temporary) state, 
the situation of serious illness. The threat of impending death – a threat to one’s very existence – 
created vulnerability through desperation. The fourth form of vulnerability potentially applied to all 
consumers in that it arose from the unknown and perhaps unknowable dangerousness of a drug. As 
noted, the issue of drug safety was very real to participants due to their own experience of side 
effects. Even an active consumer who conducted their own research and had found a good doctor 
might take a dangerous drug if its toxicity was not yet properly understood, and being alerted to a 
drug by marketing may increase the likelihood of this occurring.  
In these participants’ accounts, vulnerabilities were relational, which leads us to the fifth 
type of vulnerability. A patient’s vulnerability arose in the context of relationship with a prescribing 
doctor, who might also be more or less vulnerable to both patient and industry influence. An ideal 
doctor was impervious to influence and thus could act in a patient’s best interests. Like the active 
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critical consumer, the ideal doctor seems unlikely to exist as an embodied reality. Indeed, as we have 
shown, participants presented extensive narrative evidence of the existence of bad doctors, who 
were vulnerable to the influence of patients and corporations. They used this evidence to argue 
three things. Firstly that it was necessary to be an active consumer to find an ideal doctor. Secondly 
that ‘suggestible questing consumers’ would work (and it would not be difficult) to find a bad doctor, 
generating a co-vulnerability that would lead to over prescribing and biomedicalization. Thirdly, that 
‘compliant consumers’ and ‘seriously ill consumers’ might end up with a bad doctor because they 
were not capable of doing the work needed to find a good doctor.  
To summarize, participants’ accounts resonated across theories of vulnerability rather than 
conforming to a single theory. Participants constructed vulnerability as both individual and 
relational, inhering in situations and in personal traits, and as particular (in the case of ‘questing 
suggestible’ or ‘compliant’ consumers) but also universal in that anyone could fall foul of dangerous 
drugs or serious illness. We reiterate that these discussions occurred in Australia, where consumers 
are accustomed to being relatively protected from direct pharmaceutical marketing. If this study was 
replicated in another context – for example, the U.S. market where drug marketing is very familiar – 
consumers may be less likely to construct consumers and doctors as vulnerable.    
A public policy response to consumer marketing of medicines that takes these insights into 
account would acknowledge the key importance of the concept of vulnerability. In fashioning such a 
policy the critical ethical question would therefore be: to what degree are we morally responsible or 
obligated in relation to these types of vulnerability?  Several scholars have argued that 
vulnerabilities inevitably create responsibilities. O’Neill (1996), for example, argues that just as it is 
necessary for a society to reject inclusive principles of injuring (that is, if everyone in society injures 
everyone else with impunity, society will collapse), so is it impossible to universalize indifference to 
and neglect of others. Such an argument provides a basis from which indifference and neglect of 
vulnerable persons can be rejected in particular situations. Alternatively, Goodin (1985) argues from 
cases, often case law, that moral obligations do not arise solely from their voluntary self-assumption 
by an obliged person or persons, but that special responsibilities arise both from people’s 
vulnerability and a responsible party’s unique ability to mitigate that vulnerability. For example, as 
consumers became increasingly dependent upon companies for the provision of vital products and 
services, those companies incurred an increasing moral obligation to ensure the safety of their 
products and services, an obligation which was often eventually enshrined in law.  
Space limits us from further discussion and defense of the idea that responsibility should be 
allowed as arising from vulnerability. Nonetheless, if the premise is granted, we can ask: what 
responsibilities might be generated by the particular vulnerabilities relevant to consumer marketing 
of medicines? Participants differed on this question, presenting varying conditions for universal 
rejection, universal acceptance or conditional acceptance of consumer marketing of prescription 
medicines. 
The first position, universal rejection of such marketing, arose from two assumptions: that 
there would always be vulnerable consumers and doctors, who could not be offered effective 
protection from their susceptibility to marketing and to one another because they were extremely 
difficult to identify. Participants generally accepted that all doctors were susceptible to influence in 
certain situations (e.g. due to exhaustion and pressure). In addition, any consumers might suffer 
from serious illness, and all consumers were potentially vulnerable to dangerous drugs. From this 
point of view the only remedy was to ban consumer marketing of medicines altogether. The 
introduction of such a ban would no doubt be politically complex; and in jurisdictions where 
corporations can argue a right to freedom of speech, also legally complex. The second position was 
that marketing should be rejected only if drugs had significant safety issues or were intended to 
treat severe or life threatening illness. This position de-prioritized the problem of vulnerability 
inhering in specific individuals (‘suggestible questing consumers’ and ‘compliant consumers’) but 
acknowledged that anyone will become vulnerable in the situation of serious illness, and anyone can 
 14 
be vulnerable to a dangerous drug. However this raises the question of how to define standards for 
seriousness or dangerousness. Sometimes these standards were evident: these participants, for 
example, largely ruled out consumer marketing of cancer medicines. However participants also 
recounted well-known stories in which a medicine’s severe or life-threatening side effects were 
revealed only after mass marketing. These stories suggest that a fully informed judgment about the 
toxicity profile of a drug cannot always be made before it is marketed, so the desire of these 
participants for marketing only of ‘safe’ drugs may not be practically achievable.  
The final position, taken by only a few participants, was that marketing should be universally 
accepted. This position proposed that active consumers had a right to be alerted, and made this 
proposed right the pre-eminent concern. Any responsibilities associated with vulnerabilities thus 
became implicitly less important than a right or moral imperative for individuals to act as 
autonomous agents in control of their own health care. 
We believe that our analysis provides a basis for strong reservations about the acceptability 
of consumer marketing of prescription medicines. The basis for this rejection is not the nature of 
commercial corporations or the insufficient quality of the information provided in marketing, but the 
vulnerabilities that exist in all health care relationships and which may be elevated in certain 
consumers, practitioners and situations. It also depends upon acceptance of arguments that these 
vulnerabilities create responsibilities. These participants told us that their communities will always 
contain ‘questing suggestible consumers’, ‘compliant consumers’, ‘bad’ doctors, ‘good’ doctors 
under pressure, dangerous drugs and life-threatening illnesses, all in complex relationships with 
each another. Given this, rather than asking ‘Are corporations bad?’ or ‘Is marketing a good source 
of information?’, we believe that we should be asking: ‘What does it mean for our society if we 
universalize indifference to and neglect of these vulnerabilities?’ (after O’Neill 1996) or ‘If these 
vulnerabilities exist, who might be particularly able to, and thus morally obliged to, mitigate them?’ 
(after Goodin 1985). 
Future research on consumers’ views of marketing of prescription medicines should pay 
close attention when participants say ‘It depends’.  As we have shown here, qualitative inquiry can 
take us beyond common rhetoric and pre-conceptions, enabling a re-definition of important 
questions in applied ethics. We suggest that the new insights discussed here could be explored in 
further qualitative and quantitative research. In particular, the categories generated in this small-
scale qualitative study – active and vulnerable consumers, informing versus alerting, and ‘shopping’ 
for ‘good’ or ‘bad’ doctors – could be used to design a more extensive qualitative study to explore 
the nuances and relationships between them in more depth and in different situations. In 
conclusion, as a result of our qualitative investigation, we suggest that discussions regarding 
consumer marketing of medicines should be attentive to the vulnerabilities that inhere in 
individuals, relationships and situations in healthcare, and consider closely the responsibilities that 
these vulnerabilities might create. 
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